Dianthus Therapeutics (NASDAQ:DNTH) Trading 7.4% Higher – Here’s What Happened

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shot up 7.4% on Monday . The stock traded as high as $20.31 and last traded at $20.95. 42,144 shares traded hands during mid-day trading, a decline of 84% from the average session volume of 259,438 shares. The stock had previously closed at $19.50.

Analyst Ratings Changes

Several analysts recently commented on DNTH shares. Guggenheim reiterated a “buy” rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Finally, Wedbush reissued an “outperform” rating and set a $36.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $54.33.

Dianthus Therapeutics Price Performance

The firm has a market capitalization of $702.60 million, a price-to-earnings ratio of -8.75 and a beta of 1.62. The business’s fifty day simple moving average is $20.14 and its 200 day simple moving average is $23.00.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The company had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. Equities research analysts expect that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Large investors have recently modified their holdings of the company. R Squared Ltd bought a new stake in Dianthus Therapeutics during the 4th quarter valued at $26,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter worth about $33,000. KBC Group NV acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter worth about $35,000. BNP Paribas Financial Markets bought a new position in Dianthus Therapeutics in the 4th quarter valued at about $59,000. Finally, GAMMA Investing LLC boosted its stake in Dianthus Therapeutics by 3,030.6% during the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company’s stock valued at $70,000 after purchasing an additional 3,758 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.